Tarsus Pharmaceuticals (TARS) Stock Forecast & Price Target

Tarsus Pharmaceuticals is attractive because its commercial engine is already validated by XDEMVY, which has delivered over $100M in quarterly product sales and is guided to roughly $670M-$700M in full-year 2026 net product sales, implying about 50% year-over-year growth. The company’s outlook is strengthened by expanding Demodex blepharitis penetration across an addressable base of more than 9M patients, rising eye-care-professional confidence, a direct-to-consumer campaign, and the planned addition of 15-20 new key account leaders by 2H26. Beyond the core franchise, the acquisition of iRenix adds IRX-101 as a first retinal strategic position with Phase 3 targeted for 1H27 and topline in 2028, while TP-04 and TP-05 broaden the pipeline into category-creating opportunities with no approved therapies for ocular rosacea and potential infectious-disease prevention.

Tarsus Pharmaceuticals is a highly speculative early commercial biopharmaceutical name whose valuation hinges on aggressive 2036 EPS assumptions of $11.54 and $11.88 and discounted cash flow estimates built on 2026-2036 projections, leaving limited margin for error. The outlook is negative because the company’s thesis depends on XDEMVY and other programs achieving peak commercial revenue estimates that may not materialize if market size, penetration, or pricing fall short. It also faces material funding and execution risk, including the possibility of failing to secure capital resources to fund operations while still needing continued program development and commercialization.